Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21073942 | 1.00 | KMT2A (0.38) | KMT2APTGS1PTGS2NR3C1CASP1 | |
| SCHEMBL20864022 | 1.00 | KMT2A (0.38) | KMT2APTGS1PTGS2NR3C1CASP1 | |
| SCHEMBL23286124 | 0.96 | NR3C1 (0.38) | KMT2ANR3C1CASP1SMN1; SMN2HPGD | |
| SCHEMBL22459925 | 0.92 | HDAC3 (0.41) | KMT2APTGS1PTGS2NR3C1CASP1 | |
| SCHEMBL24835046 | 0.92 | HDAC3 (0.41) | KMT2APTGS1PTGS2NR3C1CASP1 | |
| SCHEMBL23071942 | 0.92 | NR3C1 (0.41) | KMT2ANR3C1CASP1SMN1; SMN2HPGD | |
| SCHEMBL17823174 | 0.92 | PTGS1 (0.40) | KMT2APTGS1PTGS2SMN1; SMN2HPGD | |
| SCHEMBL17823173 | 0.92 | PTGS1 (0.40) | KMT2APTGS1PTGS2SMN1; SMN2HPGD | |
| SCHEMBL22990414 | 0.91 | SMN1; SMN2 (0.38) | KMT2APTGS1PTGS2NR3C1CASP1 | |
| SCHEMBL25413283 | 0.91 | KMT2A (0.37) | KMT2APTGS1PTGS2NR3C1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3868384-B1 | CYCLIC DINUCLEOTIDES AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2026-02-25 | — | — | EP | disclosed |
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2025-10-02 | — | — | US | disclosed |
| US-20250205270-A1 | ANTIBODY-DRUG CONJUGATE PRECURSORS COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-06-26 | — | — | US | disclosed |
| WO-2025109097-A2 | NOVEL NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-05-30 | — | — | WO | disclosed |
| US-20250171419-A1 | NOVEL NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-05-29 | — | — | US | disclosed |
| US-12171777-B2 | Methods of making a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-12-24 | — | — | US | disclosed |
| US-20240293554-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | SEAGEN INC (US) | 2024-09-05 | — | — | US | disclosed |
| US-11931414-B2 | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates | SEAGEN INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| WO-2023170608-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2023-09-14 | — | — | WO | disclosed |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| CN-110325543-B | Cyclic dinucleotides as STING (stimulator of interferon genes) agonists | 武田药品工业株式会社 | 2023-03-31 | — | — | CN | disclosed |
| US-20210137962-A9 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-05-13 | — | — | US | disclosed |
| US-10980825-B2 | Cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-20 | — | — | US | disclosed |
| US-20210106607-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-15 | — | — | US | disclosed |
| EP-3512861-B1 | CYCLIC DINUCLEOTIDES AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-02-17 | — | — | EP | disclosed |
| US-20200197524-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | SEATTLE GENETICS, INC. (US) | 2020-06-25 | — | — | US | disclosed |
| US-20190192549-A1 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICALS CO (JP) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | KMT2A 2385/4885PTGS1 2504/4885PTGS2 3084/4885 |
| US-11931414-B2 | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates | NAMPT, NNMT, NADK | KMT2A 1408/4885PTGS1 2780/4885PTGS2 2789/4885 |
| US-12171777-B2 | Methods of making a cyclic dinucleotide | STING1, CGAS, MAVS | KMT2A 3651/4885PTGS1 737/4885PTGS2 758/4885 |
| US-20200197524-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | NAMPT, NNMT, NADK | KMT2A 1408/4885PTGS1 2780/4885PTGS2 2789/4885 |
| US-20210106607-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | KMT2A 2385/4885PTGS1 2504/4885PTGS2 3084/4885 |
| US-20210137962-A9 | CYCLIC DINUCLEOTIDE | STING1, CGAS, MAVS | KMT2A 3307/4885PTGS1 771/4885PTGS2 1029/4885 |
| US-20240293554-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | NAMPT, NNMT, NADK | KMT2A 1408/4885PTGS1 2780/4885PTGS2 2789/4885 |
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | CBLB, CBL, CBLC | KMT2A 1486/4885PTGS1 4831/4885PTGS2 4736/4885 |
| US-10980825-B2 | Cyclic dinucleotide | STING1, CGAS, MAVS | KMT2A 3307/4885PTGS1 771/4885PTGS2 1029/4885 |
| US-20190192549-A1 | CYCLIC DINUCLEOTIDE | STING1, CGAS, MAVS | KMT2A 3307/4885PTGS1 771/4885PTGS2 1029/4885 |
| US-20250205270-A1 | ANTIBODY-DRUG CONJUGATE PRECURSORS COMPRISING A CYCLIC DINUCLEOTIDE | STING1, CGAS, TLR9 | KMT2A 2793/4885PTGS1 1893/4885PTGS2 2631/4885 |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | STING1, TLR9, CGAS | KMT2A 2385/4885PTGS1 2504/4885PTGS2 3084/4885 |
| US-20250171419-A1 | NOVEL NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF | NAMPT, NAPRT, NNMT | KMT2A 374/4885PTGS1 3574/4885PTGS2 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.